CDK4 and neoplasm: Given that the interferon response is often associated with robust immune infiltrates, there is growing evidence suggesting that CDK4/6 inhibitors can synergize with immune checkpoint inhibitors (ICIs) to enhance anti-tumor immunity and improve therapeutic outcomes27–29.